文献速递其他结缔组织病

系统性硬化症患者报告结局的患者可接受症状状态与最小临床重要差值:比较个体化物理治疗与常规治疗的随机对照试验二次分析

Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care.
PubMed 文献 · Semin Arthritis Rheum · 2018-03-27

本研究为SCLEREDUC试验(220例系统性硬化症患者,2005年9月至2010年10月随访)的二次分析,采用外部锚法估计疼痛与活动受限的患者报告结局的PASS(第75百分位法)和MCID(均值变化法)。12个月时关节疼痛VAS的PASS为53.75(95%CI 34.00至68.00),MCID均值为-6.74(SD 32.02);HAQ的PASS为1.41(95%CI 1.13至1.63),MCID均值为-0.21(SD 0.48)。作者首次提供了系统性硬化症疼痛和活动受限的PASS与MCID估计值。

要点

  • 12个月时关节疼痛VAS(范围0-100)的PASS为53.75(95%CI 34.00至68.00),MCID均值为-6.74(SD 32.02)。
  • 12个月时HAQ(范围0-3)的PASS为1.41(95%CI 1.13至1.63),MCID均值为-0.21(SD 0.48)。
  • 12个月时 scleroderma HAQ(范围0-3)的PASS为1.27(95%CI 1.07至1.62),MCID均值为-0.13(SD 0.45)。

核心结论

  • 作者首次提供了系统性硬化症疼痛和活动受限的PASS与MCID估计值。

研究设计与样本

  • 本研究为SCLEREDUC试验的二次分析,该试验为12个月随机对照试验,比较物理治疗与常规治疗在220例系统性硬化症患者中的疗效,随访时间为2005年9月至2010年10月。
  • 采用医学结局研究36项简表提取的2个外部锚评估12个月时患者自评健康状态和健康变化。
  • 自评健康为「极好」「很好」或「好」的患者归为PASS组,自评健康变化为「稍好」的患者归为MCID组。
  • 主要结局为采用第75百分位法估计的PASS和采用评分均值变化法估计的MCID,针对疼痛和活动受限。

主要发现

  • 12个月时关节疼痛视觉模拟量表(范围0-100)的PASS为53.75(95%CI 34.00至68.00),MCID均值为-6.74(SD 32.02)。
  • 12个月时健康评估问卷(HAQ,范围0-3)的PASS为1.41(95%CI 1.13至1.63),MCID均值为-0.21(SD 0.48)。
  • 12个月时硬皮病HAQ(范围0-3)的PASS为1.27(95%CI 1.07至1.62),MCID均值为-0.13(SD 0.45)。
  • 12个月时Cochin手功能量表(范围0-90)的PASS为26.00(95%CI 17.00至37.00),MCID均值为-3.38(SD 9.87)。
  • 12个月时McMaster-Toronto关节炎患者偏好残疾问卷(范围0-30)的PASS为19.40(95%CI 17.20至21.90),MCID均值为-5.69(SD 6.79)。

关键数值与推荐

  • 关节疼痛视觉模拟量表(范围0-100):PASS 53.75(95%CI 34.00至68.00),MCID均值-6.74(SD 32.02)。
  • 健康评估问卷(HAQ,范围0-3):PASS 1.41(95%CI 1.13至1.63),MCID均值-0.21(SD 0.48)。
  • 硬皮病HAQ(范围0-3):PASS 1.27(95%CI 1.07至1.62),MCID均值-0.13(SD 0.45)。
  • Cochin手功能量表(范围0-90):PASS 26.00(95%CI 17.00至37.00),MCID均值-3.38(SD 9.87)。
  • McMaster-Toronto关节炎患者偏好残疾问卷(范围0-30):PASS 19.40(95%CI 17.20至21.90),MCID均值-5.69(SD 6.79)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To estimate patient acceptable symptom state (PASS) and minimal clinically important difference (MCID) for patient-reported outcomes in systemic sclerosis (SSc). METHODS: We conducted a secondary analysis of the SCLEREDUC trial, a 12-month randomized controlled trial comparing the efficacy of physical therapy to usual care in 220 SSc patients followed-up from September 2005 to October 2010. Self-rated state and change in patient health at 12 months were assessed by using 2 external anchors extracted from the Medical Outcomes Study 36-Item Short-Form. Patients who self-rated their health as "excellent", "very good" or "good" were the PASS group and those who self-rated their health change as "somewhat better" were the MCID group. Main outcomes were the estimates of PASS by using the 75th percentile method and of MCID by using the mean change in scores method for pain and activity limitation. RESULTS: PASS (95% confidence interval) and mean (SD) MCID estimates at 12 months were 53.75 (34.00 to 68.00) and -6.74 (32.02) for the joint-pain visual analog scale (range 0-100), 1.41 (1.13 to 1.63) and -0.21 (0.48) for the Health Assessment Questionnaire (HAQ, range 0-3), 1.27 (1.07 to 1.62) and -0.13 (0.45) for the scleroderma HAQ (range 0-3), 26.00 (17.00 to 37.00) and -3.38 (9.87) for the Cochin Hand Function Scale (range 0-90), and 19.40 (17.20 to 21.90) and -5.69 (6.79) for the McMaster-Toronto Arthritis Patient Preference Disability Questionnaire (range 0-30), respectively. CONCLUSIONS: We provide, for the first time, the PASS and MCID estimates for pain and activity limitation in SSc. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00318188. First Posted: April 26, 2006.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Daste C, Rannou F, Mouthon L, et al. Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care. Semin Arthritis Rheum. 2018. PMID: 29685482. doi:10.1016/j.semarthrit.2018.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。